Another Botox Competitor: Revance Prepares Longer-Lasting RT002 For BLA Submission

A claim that RT002's duration of efficacy surpasses the leading neurotoxin – Allergan's blockbuster Botox – will be put to the test when Revance seeks US FDA approval to treat frown lines in the first half of this year. The company's Botox biosimilar with Mylan also could move forward in 2019.

Clinic of Aesthetic Medicine. Botox / Disport Procedure for men.

CEO Dan Browne insists that Revance Therapeutics Inc.'s technology is the first innovation in neuromodulators in 30 years, providing a longer-lasting botulinum toxin-based injection for aesthetic and therapeutic uses than the four approved products in this category, including Allergan PLC's market-leading blockbuster Botox (onabotulinumtoxinA).

Revance's claim that lead product candidate RT002 (daxibotulinumtoxinA) can beat the three-to-four-month duration of efficacy of existing neurotoxins by two...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.